Back to Feed
ClinicalTrials.gov|Clinical Trial
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Abstract
The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants. Phase: PHASE2 Status: RECRUITING Conditions: Lupus Erythematosus, Systemic; Lupus Nephritis Interventions: CC-97540; Fludarabine; Cyclophosphamide
Keywords
Lupus Erythematosus, SystemicLupus Nephritis